2023
Candidate biomarkers in psychiatric disorders: state of the field
Abi-Dargham A, Moeller S, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus M, Rubio J, Sanacora G, Veenstra-VanderWeele J, Krystal J. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 2023, 22: 236-262. PMID: 37159365, PMCID: PMC10168176, DOI: 10.1002/wps.21078.Peer-Reviewed Original ResearchError-related negativityAutism spectrum disorderAnxiety disordersSpectrum disorderFunctional magnetic resonance imaging (fMRI) measuresEvent-related brain potentialsPost-traumatic stress disorderSocial anxiety disorderTreatment responseCandidate biomarkersGeneralized anxiety disorderResting-state functional magnetic resonance imaging (rsfMRI) measuresDefinitive testingBrain potentialsNeuroscience literatureElectrophysiological indicesStress disorderMagnetic resonance imaging (MRI) measuresNaturalistic settingConnectomic measuresNumerous candidate biomarkersPresence of illnessMobile health toolsIndividual levelBiomarker validation process
2016
Psychological resilience in U.S. military veterans: A 2-year, nationally representative prospective cohort study
Isaacs K, Mota NP, Tsai J, Harpaz-Rotem I, Cook JM, Kirwin PD, Krystal JH, Southwick SM, Pietrzak RH. Psychological resilience in U.S. military veterans: A 2-year, nationally representative prospective cohort study. Journal Of Psychiatric Research 2016, 84: 301-309. PMID: 27814502, DOI: 10.1016/j.jpsychires.2016.10.017.Peer-Reviewed Original ResearchConceptsU.S. military veteransTrauma-exposed veteransPsychological resilienceTrauma exposureMilitary veteransResilient groupTrauma-related psychological symptomsDistressed groupHigh trauma exposureCurrent psychological distressLifetime trauma exposurePhysical health difficultiesSense of purposeProspective cohort studyDispositional gratitudePosttraumatic stressTraumatic eventsEmotional stabilityPsychological distressCurrent distressLifetime traumaAnxiety disordersDistress symptomsHealth difficultiesPsychological symptoms
2011
New Frontiers in Animal Research of Psychiatric Illness
Kaffman A, Krystal J. New Frontiers in Animal Research of Psychiatric Illness. Methods In Molecular Biology 2011, 829: 3-30. PMID: 22231804, PMCID: PMC3337084, DOI: 10.1007/978-1-61779-458-2_1.Peer-Reviewed Original ResearchConceptsPsychiatric illnessAnimal modelsMental illnessHuman psychopathologyValid animal modelCurrent animal modelsNumerous psychiatric disordersMore effective interventionsResearch Domain Criteria projectInternational ClassificationPsychiatric disordersMeasurable endophenotypesIllnessNeurodevelopmental changesSubstance abuseEffective interventionsAnxiety disordersStatistical ManualMolecular changesDevelopmental originsMental disorders diagnostic systemsCircuit developmentTranslational workAnimal researchBehavioral outcomes
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2009
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder. Biological Psychiatry 2009, 67: 365-370. PMID: 19811776, DOI: 10.1016/j.biopsych.2009.07.036.Peer-Reviewed Original ResearchConceptsCognitive behavior therapyExposure-based cognitive behavior therapyD-cycloserinePanic disorderTherapeutic learningPanic Disorder Severity ScaleInternal sensationsManualized cognitive behavior therapyPlacebo-controlled augmentation trialD-cycloserine augmentationLarge effect sizesExposure interventionDCS administrationPill placeboAnxiety disordersDSM-IV criteriaSession 3Global ImpressionEffect sizePrimary outcome measureClinician Global ImpressionDisordersParticipantsLearningSignificant adverse effectsNeuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzole
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders
1996
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies
Bremner J, Krystal J, Southwick S, Charney D. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 1996, 23: 39-51. PMID: 8723134, DOI: 10.1002/(sici)1098-2396(199605)23:1<39::aid-syn5>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderBlood pressureNoradrenergic functionHeart rateNoradrenergic systemClinical studiesAdrenergic receptorsPanic disorderAnxiety disordersGrowth hormone responseMeasurement of norepinephrineNorepinephrine responseNoradrenergic mechanismsBaseline norepinephrineNoradrenergic responsivenessPharmacological challengeCatecholaminergic functionHormone responseTraumatic remindersPatientsAcute stressorStress disorderNorepinephrineBaseline measuresConsistent findingThe biological basis of panic disorder.
Krystal JH, Deutsch DN, Charney DS. The biological basis of panic disorder. The Journal Of Clinical Psychiatry 1996, 57 Suppl 10: 23-31; discussion 32-3. PMID: 8917129.Peer-Reviewed Original ResearchConceptsPanic disorderMultiple neuronal systemsRelated brain regionsFunctional imaging studiesOvert historyPharmacologic mechanismsTreatment optionsPharmacologic challengePanicogenic agentPreclinical investigationsNeurochemical substratesPanic attacksChallenge studiesBrain regionsImaging studiesAnatomical basisNeuronal systemsAnxiety disordersDisordersHeritable predispositionBiological basisFurther evidence
1994
Alcohol Dependence May Be the Missing Link Between Posttraumatic Stress Disorder and Panic-Reply
Krystal J, Southwick S, Charney D. Alcohol Dependence May Be the Missing Link Between Posttraumatic Stress Disorder and Panic-Reply. JAMA Psychiatry 1994, 51: 430-430. DOI: 10.1001/archpsyc.1994.03950050090014.Peer-Reviewed Original ResearchPanic disorderPTSD symptomsΑ2-adrenergic antagonistMajor psychiatric disordersPosttraumatic stress disorderAcute alcoholOpiate withdrawalMajor depressionNoradrenergic systemHealthy subjectsPsychiatric disordersClinical reportsAlcohol consumptionPatientsPanic attacksAlcohol dependenceSubstance abuseStress disorderNeurobiological significanceAnxiety disordersDisordersSymptomsPTSDWithdrawalLittle evidence